Identifying novel molecular drug targets for TNBCs that have no indications for endocrine therapy, and more efficacious therapy for Her2-positive breast cancer has therefore become extremely imperative in developing effective treatment strategies for breast cancer patients. The gene discussed is ERBB2; the disease is breast carcinoma.